From MarketBeat:

Catalent (NYSE:CTLT) was upgraded by StockNews.com to a “sell” rating, following opinions from various other analysts. The current average price target for the stock is $50.45. (50 words)

Catalent stock traded up $2.75 on Tuesday, reaching $49.41. The company has a market cap of $8.93 billion and has a 1 year low of $31.45 and a 1 year high of $74.49. They have reported a negative net margin of 22.36% and EPS of ($0.10) for the quarter. (50 words)

Institutional investors and hedge funds such as Cetera Advisor Networks LLC and Private Advisor Group LLC have made changes to their positions in CTLT. Dimensional Fund Advisors LP owns 991,019 shares of the company’s stock, the most out of those named. (50 words)

Catalent, Inc develops and manufactures solutions for drugs, protein-based biologics, and consumer health products worldwide. It operates in two segments, Biologics, and Pharma and Consumer Health. The Biologics segment provides formulation, development, and manufacturing for biologic proteins, cell gene, and other nucleic acid therapies. (50 words)



Read more: Catalent (NYSE:CTLT) Stock Rating Upgraded by StockNews.com